BPI
ADMA icon

BFC Planning, Inc.’s ADMA Biologics ADMA Stock Holding History

BFC Planning, Inc.’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-90
Closed -$811 – 3425
2026
Q1 		$811 Buy
+90
New +$1.42K ﹤0.01% 2778
2025
Q3 		– Sell
-77
Closed -$1.4K – 2897
2025
Q2 		$1.4K Buy
+77
New +$1.57K ﹤0.01% 2386

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Rubric Capital Management (New York)
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Caligan Partners
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

BFC Planning, Inc.'s ADMA Position: Q2 2026 in Review

BFC Planning, Inc. sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 90 shares — an estimated $811 sold.

BFC Planning, Inc. first reported a position in ADMA in Q2 2025 and held it in 2 quarters. The position peaked at $1.4K in Q2 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • BFC Planning, Inc. reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
  • BFC Planning, Inc. sold 90 ADMA Biologics shares in Q2 2026, an estimated $811.
  • BFC Planning, Inc. first reported a position in ADMA Biologics in Q2 2025 and held it in 2 quarters.
  • BFC Planning, Inc.'s ADMA Biologics position peaked at $1.4K in Q2 2025.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on BFC Planning, Inc.'s 13F filing for Q2 2026, filed 29 Oct 2026.